Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021.
Adolescent
Adult
Aged
Child
Child, Preschool
Female
Humans
Male
Middle Aged
Young Adult
Bayes Theorem
COVID-19
/ complications
Fatigue
/ epidemiology
Pain
/ epidemiology
SARS-CoV-2
Syndrome
Cognition Disorders
/ epidemiology
Respiratory Insufficiency
/ epidemiology
Internationality
Global Health
/ statistics & numerical data
Mood Disorders
/ epidemiology
Post-Acute COVID-19 Syndrome
Journal
JAMA
ISSN: 1538-3598
Titre abrégé: JAMA
Pays: United States
ID NLM: 7501160
Informations de publication
Date de publication:
25 10 2022
25 10 2022
Historique:
pubmed:
11
10
2022
medline:
28
10
2022
entrez:
10
10
2022
Statut:
ppublish
Résumé
Some individuals experience persistent symptoms after initial symptomatic SARS-CoV-2 infection (often referred to as Long COVID). To estimate the proportion of males and females with COVID-19, younger or older than 20 years of age, who had Long COVID symptoms in 2020 and 2021 and their Long COVID symptom duration. Bayesian meta-regression and pooling of 54 studies and 2 medical record databases with data for 1.2 million individuals (from 22 countries) who had symptomatic SARS-CoV-2 infection. Of the 54 studies, 44 were published and 10 were collaborating cohorts (conducted in Austria, the Faroe Islands, Germany, Iran, Italy, the Netherlands, Russia, Sweden, Switzerland, and the US). The participant data were derived from the 44 published studies (10 501 hospitalized individuals and 42 891 nonhospitalized individuals), the 10 collaborating cohort studies (10 526 and 1906), and the 2 US electronic medical record databases (250 928 and 846 046). Data collection spanned March 2020 to January 2022. Symptomatic SARS-CoV-2 infection. Proportion of individuals with at least 1 of the 3 self-reported Long COVID symptom clusters (persistent fatigue with bodily pain or mood swings; cognitive problems; or ongoing respiratory problems) 3 months after SARS-CoV-2 infection in 2020 and 2021, estimated separately for hospitalized and nonhospitalized individuals aged 20 years or older by sex and for both sexes of nonhospitalized individuals younger than 20 years of age. A total of 1.2 million individuals who had symptomatic SARS-CoV-2 infection were included (mean age, 4-66 years; males, 26%-88%). In the modeled estimates, 6.2% (95% uncertainty interval [UI], 2.4%-13.3%) of individuals who had symptomatic SARS-CoV-2 infection experienced at least 1 of the 3 Long COVID symptom clusters in 2020 and 2021, including 3.2% (95% UI, 0.6%-10.0%) for persistent fatigue with bodily pain or mood swings, 3.7% (95% UI, 0.9%-9.6%) for ongoing respiratory problems, and 2.2% (95% UI, 0.3%-7.6%) for cognitive problems after adjusting for health status before COVID-19, comprising an estimated 51.0% (95% UI, 16.9%-92.4%), 60.4% (95% UI, 18.9%-89.1%), and 35.4% (95% UI, 9.4%-75.1%), respectively, of Long COVID cases. The Long COVID symptom clusters were more common in women aged 20 years or older (10.6% [95% UI, 4.3%-22.2%]) 3 months after symptomatic SARS-CoV-2 infection than in men aged 20 years or older (5.4% [95% UI, 2.2%-11.7%]). Both sexes younger than 20 years of age were estimated to be affected in 2.8% (95% UI, 0.9%-7.0%) of symptomatic SARS-CoV-2 infections. The estimated mean Long COVID symptom cluster duration was 9.0 months (95% UI, 7.0-12.0 months) among hospitalized individuals and 4.0 months (95% UI, 3.6-4.6 months) among nonhospitalized individuals. Among individuals with Long COVID symptoms 3 months after symptomatic SARS-CoV-2 infection, an estimated 15.1% (95% UI, 10.3%-21.1%) continued to experience symptoms at 12 months. This study presents modeled estimates of the proportion of individuals with at least 1 of 3 self-reported Long COVID symptom clusters (persistent fatigue with bodily pain or mood swings; cognitive problems; or ongoing respiratory problems) 3 months after symptomatic SARS-CoV-2 infection.
Identifiants
pubmed: 36215063
pii: 2797443
doi: 10.1001/jama.2022.18931
pmc: PMC9552043
doi:
Types de publication
Journal Article
Meta-Analysis
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1604-1615Subventions
Organisme : NINR NIH HHS
ID : K23 NR019019
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI007044
Pays : United States
Commentaires et corrections
Type : UpdateOf
Références
Eur Respir J. 2022 Feb 3;59(2):
pubmed: 34210789
Drug Discov Ther. 2021 Nov 21;15(5):254-260
pubmed: 34719599
Respir Med. 2021 Jun;182:106394
pubmed: 33901787
JAMA. 2021 Apr 20;325(15):1525-1534
pubmed: 33729425
Eur Respir J. 2021 Apr 29;57(4):
pubmed: 33303540
Infection. 2021 Aug;49(4):703-714
pubmed: 33890243
JAMA Netw Open. 2021 Jan 4;4(1):e2036142
pubmed: 33502487
MMWR Morb Mortal Wkly Rep. 2021 Sep 10;70(36):1235-1241
pubmed: 34499626
Acta Paediatr. 2021 Jul;110(7):2208-2211
pubmed: 33835507
Nat Med. 2020 Jul;26(7):1017-1032
pubmed: 32651579
BMJ. 2021 Jul 26;374:n1648
pubmed: 34312178
Lancet Child Adolesc Health. 2021 Jun;5(6):e22-e23
pubmed: 33891880
Clin Microbiol Infect. 2021 Oct;27(10):1507-1513
pubmed: 34111579
Crit Care. 2021 Jan 25;25(1):37
pubmed: 33494766
BMJ. 2020 Aug 11;370:m3026
pubmed: 32784198
Mayo Clin Proc. 2021 Jul;96(7):1782-1791
pubmed: 34218857
Nat Med. 2021 Apr;27(4):626-631
pubmed: 33692530
J Med Virol. 2021 Feb;93(2):1013-1022
pubmed: 32729939
Clin Exp Allergy. 2021 Sep;51(9):1107-1120
pubmed: 34351016
J Med Virol. 2021 Dec;93(12):6566-6574
pubmed: 34255355
Infection. 2020 Aug;48(4):619-626
pubmed: 32535877
J Infect. 2021 Mar;82(3):378-383
pubmed: 33450302
JAMA. 2022 Feb 08;327(6):559-565
pubmed: 35072716
Arch Bronconeumol. 2021 Apr;57:59-61
pubmed: 34629656
Thorax. 2021 Apr;76(4):396-398
pubmed: 33172844
Bioessays. 2012 Dec;34(12):1050-9
pubmed: 23012250
Ann Intern Med. 2020 Sep 1;173(5):362-367
pubmed: 32491919
Clin Microbiol Infect. 2021 Feb;27(2):258-263
pubmed: 33031948
World J Pediatr. 2021 Oct;17(5):495-499
pubmed: 34478045
Lancet Respir Med. 2021 Feb;9(2):129
pubmed: 33453162
J Res Med Sci. 2022 Aug 30;27:65
pubmed: 36353352
Int J Gen Med. 2021 Aug 26;14:4829-4836
pubmed: 34471377
Lancet. 2021 Jan 16;397(10270):220-232
pubmed: 33428867
Nature. 2021 Jun;594(7862):259-264
pubmed: 33887749
PLoS One. 2021 Aug 26;16(8):e0256142
pubmed: 34437579
PLoS Med. 2016 Jun 28;13(6):e1002056
pubmed: 27351744
Clin Nurs Res. 2022 Nov;31(8):1390-1398
pubmed: 36154716
JAMA. 2020 Aug 11;324(6):603-605
pubmed: 32644129
J Infect. 2021 Apr;82(4):e31-e33
pubmed: 33373650
JAMA Netw Open. 2021 May 3;4(5):e2111417
pubmed: 34037731
Lancet Child Adolesc Health. 2022 Apr;6(4):240-248
pubmed: 35143771
BMC Health Serv Res. 2021 Aug 21;21(1):847
pubmed: 34419032
Am J Emerg Med. 2020 Jul;38(7):1504-1507
pubmed: 32317203
Lancet. 2022 Jun 18;399(10343):2263-2264
pubmed: 35717982
Ann Intern Med. 2021 Apr;174(4):576-578
pubmed: 33175566
Int J Infect Dis. 2021 Aug;109:209-216
pubmed: 34273510
BMJ Open. 2021 Aug 26;11(8):e052838
pubmed: 34446502
Epidemiol Infect. 2021 Jan 19;149:e32
pubmed: 33461632
J Infect. 2020 Dec;81(6):e4-e6
pubmed: 32853602
Crit Care Med. 2012 Feb;40(2):502-9
pubmed: 21946660
Clin Microbiol Infect. 2021 Jan;27(1):89-95
pubmed: 32979574
Clin Infect Dis. 2021 Aug 2;73(3):e826-e829
pubmed: 33624010
Lancet Child Adolesc Health. 2021 Oct;5(10):708-718
pubmed: 34358472
Clin Microbiol Infect. 2021 Feb 16;:
pubmed: 33607252
Clin Infect Dis. 2021 Dec 6;73(11):e4058-e4063
pubmed: 33252665
Lancet. 2022 Apr 16;399(10334):1469-1488
pubmed: 35219376
Physiother Theory Pract. 2020 Jun;36(6):663-668
pubmed: 32419564
Eur Respir J. 2021 Sep 16;58(3):
pubmed: 33574080
Thorax. 2021 Apr;76(4):399-401
pubmed: 33273026
Swiss Med Wkly. 2021 Sep 13;151:w30091
pubmed: 34694106
J Gen Intern Med. 2021 Dec;36(12):3772-3777
pubmed: 34355349
Microorganisms. 2021 Aug 12;9(8):
pubmed: 34442798
J Clin Immunol. 2021 Oct;41(7):1490-1501
pubmed: 34273064
Nat Med. 2021 Apr;27(4):601-615
pubmed: 33753937
Open Forum Infect Dis. 2021 Jul 16;8(8):ofab384
pubmed: 34386546
BMJ. 2006 Sep 16;333(7568):575
pubmed: 16950834
PLoS One. 2021 Dec 7;16(12):e0260568
pubmed: 34874962
Pan Afr Med J. 2020 Dec 01;37:289
pubmed: 33654513
Eur J Neurol. 2021 Oct;28(10):3348-3359
pubmed: 33682276
Lancet. 2022 Jun 25;399(10344):2351-2380
pubmed: 35405084
Drug Discov Ther. 2021;15(3):156-161
pubmed: 34234065
BMC Neurol. 2011 Mar 24;11:37
pubmed: 21435231
JAMA Netw Open. 2021 Feb 1;4(2):e210830
pubmed: 33606031
Lancet Reg Health Eur. 2021 Sep;8:100186
pubmed: 34386785
PLoS One. 2021 Apr 8;16(4):e0249644
pubmed: 33831043